These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7505197)

  • 1. Generation of cytotoxic T-lymphocytes to a self-peptide/class I complex: a model for peptide-mediated tumor rejection.
    Tjoa BA; Kranz DM
    Cancer Res; 1994 Jan; 54(1):204-8. PubMed ID: 7505197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Meth A sarcoma-derived class I major histocompatibility complex-associated peptides recognized by a specific CD8+ cytotoxic T lymphocyte.
    Frassanito MA; Mayordomo JI; DeLeo RM; Storkus WJ; Lotze MT; DeLeo AB
    Cancer Res; 1995 Jan; 55(1):124-8. PubMed ID: 7528638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with T cell receptor peptides primes anti-receptor cytotoxic T lymphocytes (CTL) and anergizes T cells specifically recognized by these CTL.
    Kuhröber A; Schirmbeck R; Reimann J
    Eur J Immunol; 1994 May; 24(5):1172-80. PubMed ID: 7514132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of CTL in vivo by major histocompatibility complex class I-peptide complexes covalently associated on the cell surface.
    Anjuère F; Horvath C; Cerottini JC; Luescher IF
    Eur J Immunol; 1995 Jun; 25(6):1535-40. PubMed ID: 7614979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use.
    Engelhard VH; Bullock TN; Colella TA; Mullins DW
    Cancer J; 2000 May; 6 Suppl 3():S272-80. PubMed ID: 10874498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Localization of two cytotoxic T lymphocyte epitopes and three anchoring residues on a single nonameric peptide that binds to H-2Ld and is recognized by cytotoxic T lymphocytes against mouse tumor P815.
    Van den Eynde B; Mazarguil H; Lethé B; Laval F; Gairin JE
    Eur J Immunol; 1994 Nov; 24(11):2740-5. PubMed ID: 7525302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue distribution of natural peptides derived from a ubiquitous dehydrogenase, including a novel liver-specific peptide that demonstrates the pronounced specificity of low affinity T cell reactions.
    Wu MX; Tsomides TJ; Eisen HN
    J Immunol; 1995 May; 154(9):4495-502. PubMed ID: 7536771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy with dendritic cells and tumor major histocompatibility complex class I-derived peptides requires a high density of antigen on tumor cells.
    Rawson P; Hermans IF; Huck SP; Roberts JM; Pircher H; Ronchese F
    Cancer Res; 2000 Aug; 60(16):4493-8. PubMed ID: 10969797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA vaccination primes MHC class I-restricted, simian virus 40 large tumor antigen-specific CTL in H-2d mice that reject syngeneic tumors.
    Schirmbeck R; Böhm W; Reimann J
    J Immunol; 1996 Oct; 157(8):3550-8. PubMed ID: 8871655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of peptide-specific CD8+ CTL clones in beta 2-microglobulin-deficient mice.
    Cook JR; Solheim JC; Connolly JM; Hansen TH
    J Immunol; 1995 Jan; 154(1):47-57. PubMed ID: 7995959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylcholanthrene-induced mouse sarcomas express individually distinct major histocompatibility complex class I-associated peptides recognized by specific CD8+ T-cell lines.
    Kono K; Petersson M; Ciupitu AM; Wen T; Klein G; Kiessling R
    Cancer Res; 1995 Dec; 55(23):5648-55. PubMed ID: 7585649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells.
    Yanuck M; Carbone DP; Pendleton CD; Tsukui T; Winter SF; Minna JD; Berzofsky JA
    Cancer Res; 1993 Jul; 53(14):3257-61. PubMed ID: 7686815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of cloned class I MHC-restricted, CD8+ anti-Meth A cytotoxic T-lymphocytes: recognition of an epitope derived from the Meth A gp110 tumor rejection antigen.
    Fassanito MA; Loftus D; De Leo RM; Law LW; Appella E; De Leo AB
    Cancer Res; 1994 Aug; 54(16):4424-9. PubMed ID: 7519121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells.
    Bianchi R; Grohmann U; Belladonna ML; Silla S; Fallarino F; Ayroldi E; Fioretti MC; Puccetti P
    J Immunol; 1996 Aug; 157(4):1589-97. PubMed ID: 8759743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts.
    Nagata Y; Furugen R; Hiasa A; Ikeda H; Ohta N; Furukawa K; Nakamura H; Furukawa K; Kanematsu T; Shiku H
    J Immunol; 1997 Aug; 159(3):1336-43. PubMed ID: 9233630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo priming of cytotoxic T lymphocyte responses in relation to in vitro up-regulation of major histocompatibility complex class I molecules by short synthetic peptides.
    Zhou X; Abdel Motal UM; Berg L; Jondal M
    Eur J Immunol; 1992 Dec; 22(12):3085-90. PubMed ID: 1446701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity.
    Morgan DJ; Kreuwel HT; Fleck S; Levitsky HI; Pardoll DM; Sherman LA
    J Immunol; 1998 Jan; 160(2):643-51. PubMed ID: 9551898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A self-reactive class I-restricted T-cell response of H-2b mice to determinants of the V beta 8.2 domain of the T-cell receptor for antigen.
    Kuhröber A; Schirmbeck R; Reimann J
    Immunology; 1994 Dec; 83(4):532-9. PubMed ID: 7533132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a murine mutant Ras CD8+ CTL peptide epitope variant that possesses enhanced MHC class I binding and immunogenic properties.
    Bristol JA; Schlom J; Abrams SI
    J Immunol; 1998 Mar; 160(5):2433-41. PubMed ID: 9498787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased threshold for TCR-mediated signaling controls self reactivity of intraepithelial lymphocytes.
    Guehler SR; Finch RJ; Bluestone JA; Barrett TA
    J Immunol; 1998 Jun; 160(11):5341-6. PubMed ID: 9605133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.